Gérard M, Defresne N, Daneau D, Van der Auwera P, Delmée M, Bourguignon A M, Meunier F
Service de Médecine Interne, Institut Jules Bordet, Brussels, Belgium.
Eur J Clin Microbiol Infect Dis. 1988 Apr;7(2):274-8. doi: 10.1007/BF01963101.
The aim of the study was to assess the incidence and clinical significance of Clostridium difficile in patients in our cancer center. Over a period of seven consecutive months, 557 stools samples obtained from 156 hospitalized cancer patients (37 leukemic patients receiving oral antimicrobial prophylaxis and 119 patients from whom a stool sample was sent to the laboratory) were analyzed for the presence of Clostridium difficile. Clostridium difficile and/or its toxin was recovered from 13 (35%) of the 37 patients receiving oral antimicrobial prophylaxis, and from 15 (12%) of the other 119 patients (p less than 0.05). Isolation of Clostridium difficile was associated with diarrhoea in 13 (46%) of 28 patients but specific treatment was initiated only in 7 (25%) of the 28 patients in whom Clostridium difficile was isolated. The wide distribution of the serotypes identified in our patients does not suggest an epidemic situation in our hospital.
本研究的目的是评估我院癌症中心患者艰难梭菌的发生率及临床意义。在连续七个月的时间里，对从156名住院癌症患者（37名接受口服抗菌药物预防的白血病患者和119名送检粪便样本的患者）获取的557份粪便样本进行艰难梭菌检测。在37名接受口服抗菌药物预防的患者中，有13名（35%）检测出艰难梭菌和/或其毒素；在其他119名患者中，有15名（12%）检测出（p<0.05）。在28名艰难梭菌检测呈阳性的患者中，有13名（46%）出现腹泻，但在这28名患者中，只有7名（25%）开始接受特异性治疗。在我们的患者中鉴定出的血清型分布广泛，这表明我院未出现疫情。
